Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q4 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 18, 2026
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $32K for the fourth quarter 2025 (Q4 2025), -100% from a year earlier and -91% from the quarter before.
NewAmsterdam Pharma Co N.V., Q4 2025: revenue $32K (-100% year over year), net loss $74.9M, operating cash flow −$40.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32K | -91% | -100% |
| Operating profit | −$66.0M | — | — |
| Net earnings | −$74.9M | — | — |
| Operating cash flow | −$40.9M | — | — |
What changed
Revenue was $32K in Q4 2025, down 100% year over year and down 91% from the previous quarter.
Operating costs exceeded revenue by $66.0M, an operating margin of -206187.5%. Total costs grew 18% against a revenue fall of 100%. The fastest-growing cost line was SG&A (+30%). The quarter ended with a net loss of $74.9M, wider than the previous quarter's $72.0M loss.
Operating cash flow was −$40.9M. Non-cash charges added back $59K of depreciation and amortization and $14.0M of share-based compensation. Working capital and other items added $20.0M. Capital expenditures of $100K exceeded it, leaving free cash flow of −$41.0M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the fourth quarter 2025?
NewAmsterdam Pharma Co N.V.